EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback